Search the Site

Twitter

test tubes

Sanofi-Aventis's Prowl for New Insulin, Could it be Biodel's Linjeta?

publication date: Sep 28, 2010
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
Last week, Sanofi-Aventis (NYSE: SNY) confirmed that it is on the prowl for diabetes partnerships. Bloomberg reported statements made by Riccardo Perfetti, the Senior Medical Director for Sanofi-Aventis’ diabetes unit, that Sanofi-Aventis may unveil...


Sorry this page is available to subscribers only. If you're not a subscriber why not join today?

You can also sign up for our 100% FREE Newsletter  to stay current on public webinars, special offers, and news alerts:

FREE NEWSLETTER

If you are already a subscriber, please login.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site including:

- Detailed Reports on Upcoming FDA and Clinical Trial Trades
- REAL TIME Posting of Trades (Entries and Exits)
- Clinical and Regualtory Catalyst Database with over 300 events and updated daily 
- Members Only Live Interactive Webinars 
- Weekly Watchlist
- Email / SMS (Text Message) Alerts of critical news
- Access to view Mark Messier and Mike Havrilla's Trading Accounts
- A More Detailed FDA Calendar
- Direct Email Communication
- Affiliate Program

If you believe you should be able to view this area then please contact us and we will try to rectify this issue as soon as possible.